showed that AGL serves as a prognostic marker for bladder cancer survival, and decreased AGL enhances tumor growth by increasing glycine synthesis through increased expression of serine hydroxymethyltransferase 2 (SHMT2), an enzyme that allows cells to process glycogen into glycine (62). The gene discussed is SHMT2; the disease is urinary bladder cancer.